391 related articles for article (PubMed ID: 37569693)
1. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
Wei W; Chen ZN; Wang K
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
4. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
5. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
7. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
8. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
9. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
Sterner RM; Cox MJ; Sakemura R; Kenderian SS
J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
[TBL] [Abstract][Full Text] [Related]
11. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology.
Tao R; Han X; Bai X; Yu J; Ma Y; Chen W; Zhang D; Li Z
Front Immunol; 2024; 15():1354825. PubMed ID: 38449862
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
13. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
16. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X
Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635
[TBL] [Abstract][Full Text] [Related]
17. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
[TBL] [Abstract][Full Text] [Related]
19. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]